Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations
PURPOSE: Lynch syndrome (LS) screening can significantly reduce cancer morbidity and mortality in mutation carriers. Our aim was to identify cost-effective LS screening programs that can be implemented in the "real world.".
METHODS: We performed a systematic review of full economic evaluations of genetic screening for LS in different target populations; health outcomes were estimated in life-years gained or quality-adjusted life-years.
RESULTS: Overall, 20 studies were included in the systematic review. Based on the study populations, we identified six categories of LS screening program: colorectal cancer (CRC)-based, endometrial cancer-based, general population-based, LS family registry-based, cascade testing-based, and genetics clinic-based screening programs. We performed an in-depth analysis of CRC-based LS programs, classifying them into three additional subcategories: universal, age-targeted, and selective. In five studies, universal programs based on immunohistochemistry, either alone or in combination with the BRAF test, were cost-effective compared with no screening, while in two studies age-targeted programs with a cutoff of 70 years were cost-effective when compared with age-targeted programs with lower age thresholds.
CONCLUSION: Universal or <70 years-age-targeted CRC-based LS screening programs are cost-effective and should be implemented in the "real world.".
| Errataetall: |
CommentIn: Genet Med. 2019 Jan;21(1):254-255. - PMID 29740168 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Genetics in medicine : official journal of the American College of Medical Genetics - 20(2018), 10 vom: 04. Okt., Seite 1131-1144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Marco, Marco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF protein, human |
|---|
| Anmerkungen: |
Date Completed 26.02.2019 Date Revised 08.04.2022 published: Print-Electronic CommentIn: Genet Med. 2019 Jan;21(1):254-255. - PMID 29740168 Citation Status MEDLINE |
|---|
| doi: |
10.1038/gim.2017.244 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279634692 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279634692 | ||
| 003 | DE-627 | ||
| 005 | 20231225023431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/gim.2017.244 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0932.xml |
| 035 | |a (DE-627)NLM279634692 | ||
| 035 | |a (NLM)29300371 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Marco, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2019 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Genet Med. 2019 Jan;21(1):254-255. - PMID 29740168 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Lynch syndrome (LS) screening can significantly reduce cancer morbidity and mortality in mutation carriers. Our aim was to identify cost-effective LS screening programs that can be implemented in the "real world." | ||
| 520 | |a METHODS: We performed a systematic review of full economic evaluations of genetic screening for LS in different target populations; health outcomes were estimated in life-years gained or quality-adjusted life-years | ||
| 520 | |a RESULTS: Overall, 20 studies were included in the systematic review. Based on the study populations, we identified six categories of LS screening program: colorectal cancer (CRC)-based, endometrial cancer-based, general population-based, LS family registry-based, cascade testing-based, and genetics clinic-based screening programs. We performed an in-depth analysis of CRC-based LS programs, classifying them into three additional subcategories: universal, age-targeted, and selective. In five studies, universal programs based on immunohistochemistry, either alone or in combination with the BRAF test, were cost-effective compared with no screening, while in two studies age-targeted programs with a cutoff of 70 years were cost-effective when compared with age-targeted programs with lower age thresholds | ||
| 520 | |a CONCLUSION: Universal or <70 years-age-targeted CRC-based LS screening programs are cost-effective and should be implemented in the "real world." | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a DAndrea, Elvira |e verfasserin |4 aut | |
| 700 | 1 | |a Panic, Nikola |e verfasserin |4 aut | |
| 700 | 1 | |a Baccolini, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Migliara, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Marzuillo, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a De Vito, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Pastorino, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Boccia, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Villari, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genetics in medicine : official journal of the American College of Medical Genetics |d 1997 |g 20(2018), 10 vom: 04. Okt., Seite 1131-1144 |w (DE-627)NLM097536970 |x 1530-0366 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2018 |g number:10 |g day:04 |g month:10 |g pages:1131-1144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/gim.2017.244 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2018 |e 10 |b 04 |c 10 |h 1131-1144 | ||